Replimune announces USD55m from its Series B financing with investors.
M2 PHARMA-September 11, 2017-Replimune announces USD55m from its Series B financing with investors
(C)2017 M2 COMMUNICATIONS
Biotechnology company Replimune Group Inc stated on Friday that it has raised USD55m under its Series B financing.
According to the company, the proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP1, in multiple tumor types, as well as to advance further product candidates from its Immulytic platform for the treatment of cancer.
This financing was led by Foresite Capital as well as other new investors including Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management and entities affiliated with Leerink Partners. All of the company's existing investors; Atlas Venture, Forbion Capital Partners and Omega Funds, also participated.
In conjunction, Dr Brett Zbar from Foresite Capital and Dr Kapil Dhingra, prior head of clinical oncology at Roche and currently an advisor to Replimune, will join Replimune's board of directors, respectively. Additionally, Replimune has elected Howard Kaufman, MD, FACS, as its new chief medical officer.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 11, 2017|
|Previous Article:||Zavante Therapeutics partners with NIAID to assess ZOLYD for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.|
|Next Article:||Replimune names Howard L. Kaufman, MD, FACS as CMO.|